# US 2008/0305092 A1 · Methods of treating autoimmune disease via CTLA-4IG

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305092 A1
- Document ID: US20080305092A1
- Status: Published application
- Kind: A1
- Application number: 12/044,679
- Filed: 2008-03-07
- Published: 2008-12-11
- Earliest claimed: 1993-06-10
- Assignees: The Regents of the University of Michigan
- Inventors: Craig B. Thompson; Carl H. June
- Web page: https://patentgrep.com/patent/US20080305092A1

## CPC

- C07K 14/70521: {CD28, CD152}
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/2818: {against CD28 or CD152}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The method of immunotherapy of the present invention involves the regulation of the T cell immune response through the activation or suppression/inactivation of the CD28 pathway. Induction of activated T cell lymphokine production occurs upon stimulatory binding of the CD28 surface receptor molecule, even in the presence of conventional immunosuppressants. Inhibition of CD28 receptor binding to an appropriate stimulatory ligand or inactivation of the CD28 signal transduction pathway through other means down-regulates CD28-pathway related T cell lymphokine production and its resulting effects.

## Claims

### Claim 1

A method of inhibiting CD28 pathway activation associated with an increase in cellular production of a THCD28 lymphokine in a T cell population, wherein activation occurs by the binding of a stimulatory CD28 ligand to a CD28 receptor stimulatory binding site, the method comprising the steps of:
a) selecting an inhibitory ligand capable of binding to the stimulatory CD28 ligand;
b) providing the inhibitory ligand in a biologically compatible form; and
c) administering the inhibitory ligand to the population in an amount sufficient to bind and inhibit the stimulatory ligand from binding the CD28 receptor stimulatory binding site.

### Claim 2 (depends on 1)

The method of claim 1, wherein the stimulatory ligand comprises a natural CD28 ligand.

### Claim 3 (depends on 1)

The method of claim 1, wherein the inhibitory ligand comprises an antibody or fragment thereof to the stimulatory ligand.

### Claim 4 (depends on 1)

The method of claim 1, wherein the inhibitory ligand comprises a soluble form of CTLA-4.

### Claim 5 (depends on 4)

The method of claim 4, wherein the ligand comprises CTLA-4Ig.

### Claim 6 (depends on 1)

The method of claim 1, wherein the inhibitory ligand is of synthetic origin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the inhibitory ligand comprises a recombinant molecule.

### Claim 8 (depends on 1)

The method of claim 1, further comprising the step of:
d) administering a second inhibitory ligand capable of binding but not stimulating the CD28 receptor binding site.

### Claim 9

A method of suppressing the production of a THCD28 lymphokine by a population of T cells, the method comprising the steps of:
a) administering an inhibitory ligand which binds a stimulatory ligand for CD28;
b) providing the ligand in biologically compatible form; and
c) administering the provided ligand in an amount sufficient to suppress production of the lymphokine in the population.

### Claim 10 (depends on 9)

The method of claim 9, wherein the inhibitory ligand comprises a soluble form of CTLA-4.

### Claim 11 (depends on 10)

The method of claim 10, wherein the inhibitory ligand comprises CTLA-4Ig.

### Claim 12 (depends on 9)

The method of claim 9, wherein the T cell population is in a patient in an autoimmune state.

### Claim 13

A method of suppressing THCD28 lymphokine production in a patient having a population of T cells, the method comprising the steps of:
a) providing an inhibitory ligand which binds a natural stimulatory ligand for CD28; and
b) administering the inhibitory ligand in a therapeutically effective amount to the population of T cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein the administration of the ligand to the population of T cells is in vivo.

### Claim 15 (depends on 13)

The method of claim 13, wherein the administration of the ligand to the population of T cells is in vitro, and further comprising the step of:
d) introducing the population of T cells into the patient after administration.

### Claim 16 (depends on 15)

The method of claim 15, wherein the T cell population is removed from the patient prior to ligand administration.

### Claim 17 (depends on 13)

The method of claim 13, wherein the inhibitory ligand comprises a soluble form of CTLA-4.

### Claim 18 (depends on 17)

The method of claim 17, wherein the inhibitory ligand comprises CTLA-4Ig.

### Claim 19

A method of treating an autoimmune disease in a patient comprising the steps of:
a) selecting an inhibitory ligand which binds a natural stimulatory ligand to CD28; and
b) administering a therapeutically effective amount of the ligand to the patient.

### Claim 20 (depends on 19)

The method of claim 19, wherein the stimulatory ligand is B7 and the inhibitory ligand comprises a soluble form of CTLA-4.

### Claim 21 (depends on 19)

The method of claim 19, wherein the inhibitory ligand comprises CTLA-4Ig.

### Claim 22 (depends on 20)

The method of claim 20, wherein the administration is in vivo.

### Claim 23 (depends on 20)

The method of claim 20, wherein the administration is in vitro to a population of cells removed from the patient, and further comprising the step of:
c) reintroducing the cells to the patient after administration.

### Claim 24 (depends on 20)

The method of claim 20, wherein the autoimmune disease is multiple sclerosis.
